Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The surface charge of nanoparticles (NPs) plays an essential role in determining their biological properties both in vitro and in vivo. In view of the complex features associated with the biological or physiological microenvironment of solid tumors, such as electrostatic interactions between NPs and serum components, cellular membrane, or intracellular organelles, drug-loaded NPs (or nanocarriers) should intelligently accommodate such unique extra- or intracellular microenvironment in order to achieve maximum therapeutic and/or diagnostic efficacy. To that end, the surface charge of nanocarriers needs to be readily converted at the target site by means of charge reversal, i.e., conversion from anionic to cationic, or vice versa, depending on specific microenvironment. In such a manner, the payloads could be efficiently released at the desired tumor site. This review discusses 1) the physicochemical aspects related to long-circulating nanocarriers for systemic applications; 2) the recent progress in charge-reversal nanocarriers, which are loaded with drugs, nucleic acids, proteins or imaging agents and triggered by various biological signals (i.e., pH, redox, ROS or enzyme) associated with tumor microenvironment, with an emphasis on those induced by acidic tumoral pH; and 3) the perspectives of charge-reversal nanocarriers regarding thorough investigations on how the chemical structure of charge-reversal moiety temporally affects the responsiveness of the resulting nanocarriers toward the rational design of precision cancer nanomedicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Mesoporous silica nanoparticles for drug delivery and biosensing applications
Slowing, I. I., Trewyn, B. G., Giri, S., & Lin, V. S. ‐. (2007) · Advanced Functional Materials · doi:10.1002/adfm.200601191 · Cited by 1,699
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Cited by
Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 680
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
“However, studies have proven that the in vivo complex microenvironment and diverse biological barriers can critically determine their therapeutic efficacy [78, 217].”
BackgroundHu, L., Xiong, C., Wei, G., Yu, Y., Li, S., Xiong, X., Zou, J.-J., & Tian, J. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.10.070 · Cited by 78
Dai, Q., Du, Z., Jing, L., Zhang, R., & Tang, W. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c11500 · Cited by 17
Advances in 2,3-Dimethylmaleic Anhydride (DMMA)-Modified Nanocarriers in Drug Delivery Systems
Wan, D., Wu, Y., Liu, Y., Liu, Y., & Pan, J. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060809 · Cited by 7
Metadata
- Authors
- Zhang, M., Chen, X., Li, C., & Shen, X.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 319
- Pages
- 46-62
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2996264612
- Cited by
- 126
- References
- 17
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.